Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460201 | 0.88 | NR1H4 (0.41) | DYRK1AYTHDC1CFTRMEN1KMT2A | |
| SCHEMBL3141473 | 0.84 | PDE4A (0.53) | FGFR1CYP11B2DYRK1ALMNAYTHDC1 | |
| SCHEMBL4466459 | 0.81 | XDH (0.43) | CFTRMEN1KMT2AXDH | |
| SCHEMBL4472575 | 0.81 | PDE4A (0.44) | XDHPOLB | |
| SCHEMBL3137687 | 0.80 | FGFR1 (0.41) | FGFR1CYP11B2DYRK1AYTHDC1 | |
| SCHEMBL4462825 | 0.78 | YTHDC1 (0.53) | LMNAYTHDC1MEN1KMT2AALDH1A1 | |
| SCHEMBL4466877 | 0.76 | XDH (0.50) | FGFR1LMNAYTHDC1HTTMEN1 | |
| SCHEMBL4474196 | 0.75 | RXRA (0.41) | XDHDHFR | |
| SCHEMBL4458819 | 0.75 | SCN9A (0.42) | YTHDC1XDH | |
| SCHEMBL4476326 | 0.73 | CSNK1D (0.36) | XDHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2009-12-31 | — | — | US | claimed |
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2008-10-30 | — | — | US | claimed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | claimed |
| CN-1688578-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | claimed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | claimed |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2009-12-31 | — | — | US | disclosed |
| WO-2009067607-A2 | COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2008-10-30 | — | — | US | disclosed |
| CN-100415747-C | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-09-03 | — | — | CN | disclosed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| CN-1688578-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | disclosed |
| EP-1551837-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | disclosed |
| WO-2004014911-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | FGFR1 1656/4885CYP11B2 166/4885DYRK1A 2584/4885 |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | FGFR1 2005/4885CYP11B2 208/4885DYRK1A 2960/4885 |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | FGFR1 1656/4885CYP11B2 166/4885DYRK1A 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.